Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of CDP-Choline (Citicoline) and Unifiram — mechanism, side effects, legal status, and pricing.
CDP-choline (citicoline) is a non-peptide cytidine nucleotide-choline conjugate that serves as an intermediate in phosphatidylcholine biosynthesis. It is approved as a prescription drug for stroke and cognitive disorders in Japan and parts of Europe but sold only as a dietary supplement ingredient in the United States, where it is not FDA-approved as a drug. Human evidence is mixed and indication-dependent: small trials report modest memory improvements in healthy/older adults, but the largest phase 3 RCT (COBRIT, n=1,213 traumatic brain injury patients) found no benefit over placebo.
Unifiram (DM-232) is a synthetic non-peptide small-molecule nootropic structurally related to sunifiram, though not a racetam itself. It originated from Italian academic research (University of Florence) in the early 2000s and has never progressed beyond preclinical animal studies; it is not an approved or investigational drug in any regulatory database. Unifiram is sold openly by research-chemical vendors as an unregulated laboratory reagent. No human data of any kind exist.
CDP-Choline (Citicoline)
Unifiram
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
CDP-Choline (Citicoline)
No pricing data yet.
Check CDP-Choline (Citicoline) prices →Unifiram
COA corpus from Disclosed Labs — independently tested batches only.
CDP-Choline (Citicoline)
No COA data yet.
Submit testing data →Unifiram
1
COAs
99.4%
Avg purity
1
Labs
Human evidence is mixed and indication-dependent. Small-to-moderate placebo-controlled RCTs in healthy/older adults and age-associated memory impairment report modest verbal/episodic memory improvements at ~500–1,000 mg/day over weeks to months. However, the largest trial to date—COBRIT, a phase 3 double-blind placebo-controlled RCT in 1,213 traumatic brain injury patients—found no benefit over placebo on functional or cognitive outcomes (GOS-E favorable outcome 35.4% citicoline vs 35.6% placebo; global OR 0.98, 95% CI 0.83–1.15). Evidence for Alzheimer's disease and MCI is described in reviews as insufficient and inconsistent. In preclinical models, aged rats with hippocampal damage showed reduced long-term memory impairment with dietary CDP-choline supplementation, and mice subjected to ischemic stroke showed SIRT1-dependent reduction in cerebral infarct volume.
Key references
No human data of any kind exist for unifiram; no registered clinical trials or published human studies were found. All available evidence is from rodent behavioral and in-vitro electrophysiology studies. In mice and rats, unifiram (0.001–1 mg/kg i.p. or 0.01–0.1 mg/kg oral) reversed amnesia induced by scopolamine, mecamylamine, baclofen, clonidine, and NBQX in passive-avoidance and Morris water-maze tests, at doses roughly 1,000-fold lower than piracetam, without impairing motor coordination or altering spontaneous locomotor activity. No systematic toxicology (repeat-dose, genotoxicity, carcinogenicity) studies have been published.
Key references
CDP-Choline (Citicoline) and Unifiram are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs